Trial · NCT04348136
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of adverse events | From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years | |
| Primary | Occurrence of adverse reactions | From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years | |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (hematology) |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (biochemistry) |
| Primary | Incidence of abnormal vital signs | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | Laboratory tests (iron-related tests) |
| Primary | Laboratory tests (urinalysis) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (pulse rate) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (body temperature) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Vital signs (blood pressure) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | 12-lead electrocardiogram | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | The presence or absence of abnormal findings (if present, specific findings and whether or not they are reported as adverse events) |
| Primary | Antibody tests (anti-JR-141 antibodies) | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | IAR | From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years | |
| Primary | Time course of developmental assessment data (Kyoto Scale of Psychological Development 2001) from initial dosing in the preceding study | Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of developmental assessment data (Vineland-II) from initial dosing in the preceding study | Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of developmental assessment data (Bayley-III or KABC-II) from initial dosing in the preceding study | Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of CSF substrate (HS and DS) concentrations from initial dosing in the preceding study | Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of serum HS and DS concentrations from initial dosing in the preceding study | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of urinary HS concentration from initial dosing in the preceding study | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of urinary DS concentration from initial dosing in the preceding study | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years | |
| Primary | Time course of uronic acid concentration from initial dosing in the preceding study | Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04348136/registered